Boston Scientific

Driving Survival Benefits: HCC & ICCA

Driving Survival Benefits in HCC and ICCA

Join leading experts at ECIO 2026 to discover how TheraSphere™
Y-90 Therapy, integrated into multidisciplinary, multimodal approaches, is redefining what’s possible in primary liver cancer.

Join our Symposium
SIRT across BCLC in HCC patients:
Expanding Survival. Enabling Cure.

Tuesday April 28^th | 12:30-13:15 CET | Auditorium 2
Prof. Pinato, Dr. Bhoori, Prof. Guiu, Dr. Ghinolfi

TheraSphere™ Y-90 Therapy’s versatility in modern MDT care.
Liver function preservation and conversion in advanced HCC.
Large tumour management to maximise outcomes.

Add to your agenda

Oral Presentations (ECIO Scientific Programme)
SP 413 – Y90 and novel therapies

Wednesday April 29^th | 08:30 CET | Auditorium 3

New insights from PROACTIF, the largest, prospective real-world Y-90 Study in patients with:

HCC and portal vein thrombosis (PVT)
Intrahepatic cholangiocarcinoma (ICCA)

Real-world evidence alongside randomised trials, reinforcing TheraSphere™ Y-90 Therapy as a key component of liver cancer care.

Book your calendar

Explore clinical insights and emerging evidence. Join our new dedicated Interventional Oncology and Embolisation LinkedIn page.

Boston Scientific International SA

www.bostonscientific.eu | Tel: +33 1 39 30 97 00

Parc Val Saint Quentin - Bâtiment H | 2 Rue René Caudron | 78960 Voisins-le-Bretonneux

VAT: FR07420668402

CAUTION

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com.
Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.
This material is not intended for use in France.

PI-2464205-AA
CⲈ 0123

Privacy Policy | Terms of Use

For questions on privacy
Contact our EU Data Protection Officer at: [email protected]
Boston Scientific
c/Ribera del Loira, 46 Edificio 2
28042 Madrid (Spain)

Driving Survival Benefits in HCC and ICCA

Join our Symposium SIRT across BCLC in HCC patients: Expanding Survival. Enabling Cure.

Oral Presentations (ECIO Scientific Programme) SP 413 – Y90 and novel therapies

Join our Symposium
SIRT across BCLC in HCC patients:
Expanding Survival. Enabling Cure.

Oral Presentations (ECIO Scientific Programme)
SP 413 – Y90 and novel therapies